Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exact Sciences

Exact Sciences, A Cathie Wood Darling, Skids Despite A Sixth Big Quarter

Exact Sciences reported another quarter of strong growth, but screening sales missed whispered forecasts and EXAS stock plummeted Wednesday.

Investors Business Daily

This Cathie Wood Stock Is Outperforming Even Tesla

Cathie Wood has bet big on 10 stocks. Tesla stock has more than doubled in 2023, but it's not the strongest performer among Ark Invest's major holdings.

Investors Business Daily

The Wild Ride That Has Sent Exact Sciences 216% Higher Since October

Exact Sciences said the company's next-generation Cologuard outperformed the original test. EXAS stock seesawed on the news.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Top 2% Stock Exact Sciences Is On An Eight-Month Hot Streak — And Just Hit A Profit-Taking Zone

The market for colon cancer screening is massive — and underserved. And that might be why EXAS stock is on an eight-month hot streak.

Investors Business Daily

Moderation in U.S. Consumer Prices Boost Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.11%. Stock indexes Wednesday settled mixed, with the S&P 500...

Barchart

Markets Today: Stocks Rally as U.S. CPI Eases

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.37%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.45%. U.S. stock index futures this morning erased overnight losses and pushed higher after U.S. consumer prices eased in April. Bond yields also fell on the...

Barchart

Exact Sciences, Guardant Health Put Up Big Sales Beats As They Target The 'Most Preventable' Cancer

Exact Sciences delivered a first-quarter report that "checked all the boxes," an analyst said as EXAS stock surged.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Reverses Ahead Of Fed Minutes; Baidu Surges On Earnings; Nvidia Earnings On Deck

The Dow Jones reversed lower Wednesday ahead of minutes from the Federal Reserve's latest policy meeting. Nvidia earnings are due out late.

Investors Business Daily

Dow Jones Futures Rise: S&P 500 Nears Key Support As Nvidia Earnings Loom; Here's What To Do Now

The Nasdaq and S&P 500 have tumbled to just above critical support as Treasury yields spike. Nvidia earnings are on tap.

Investors Business Daily

Exact Sciences, A Top 5% Stock, Beat Quarterly Expectations

Exact Sciences delivered a second consecutive quarter of sales growth acceleration and EXAS stock rose on Wednesday.

Investors Business Daily

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Investors Business Daily

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review

The stock market rally picked up steam amid cooler inflation. Sharp Tesla price cuts and some notable earnings were in focus.

Investors Business Daily

Exact Sciences Raises Fourth-Quarter Estimates Above Expectations

EXAS stock jumped as the provider of cancer screening and diagnostic tests raised estimates for its fourth quarter.

Investors Business Daily

Exact Sciences Stock Scores Relative Strength Rating Upgrade

Exact Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Closes Near Day's Lows As S&P Falls Below Key Level On Recession Concerns

The stock market extended losses to a third day on low business activity and fears of a global recession. Facebook bucked the trend.

Investors Business Daily

Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

Investors Business Daily

Cathie Wood Has Bet Big On These 10 Stocks; Here's How They Performed In 2022

Cathie Wood makes big bets on potential huge winners. But Ark Invest's top 10 holdings, including Tesla and Roku, tumbled in 2022.

Investors Business Daily

Exact Sciences Surges After Massively Beating Quarterly Forecasts, Raising Outlook

Exact Sciences massively beat third-quarter expectations and raised its full-year outlook — and EXAS stock skyrocketed on Friday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022

Upgrades

Axios

Next-gen blood tests to detect cancer and other diseases come with questions

The tests can help detect some diseases early but it's still unclear how much they affect whether someone survives a disease.

Benzinga

Expert Ratings for Exact Sciences

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Benzinga

Exact Sciences's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

Benzinga

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.

Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.

Benzinga

Preview: Exact Sciences's Earnings

Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Exact Sciences will report an earnings per share (EPS) of $-1.07.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.